Nodus Oncology
Nodus Oncology is developing first and best-in-class molecules inhibiting novel targets within the DNA damage response and replication stress response.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
* | £1.8m Valuation: £12.0m | Seed | |
| Total Funding | 000k | ||
Related Content
Nodus Oncology is a pioneering startup in the biopharmaceutical sector, focusing on the development of innovative cancer drugs. The company operates in the oncology market, which deals with the treatment and study of cancer. Nodus Oncology was founded by Clare Wareing, who has a rich background in cancer cell biology and a successful track record in clinical development within the oncology biopharmaceutical sector.
The company's core team includes highly experienced professionals such as Ian Waddell, the CEO, who has over 30 years of experience in oncology research and development (R&D), and Luis Toledo, a scientific advisor with deep expertise in the DNA Damage Response (DDR) field. Nicola Broughton, the Chief Business Officer, brings extensive experience in entrepreneurship, investment, and deal negotiation in the life sciences sector. Manuelle Debunne, the Chief Operating Officer, excels in managing both academic and industry programs to advance oncology assets towards clinical development. Scott Doak, the Chief Financial Officer, adds financial expertise to the team.
Nodus Oncology serves a range of clients, including biotech companies and research institutions focused on developing new cancer therapies. The company operates in the highly specialized oncology market, targeting unmet medical needs in cancer treatment.
The business model of Nodus Oncology revolves around leveraging its scientific expertise and commercial strategy to develop multiple drug development programs. These programs aim to bring innovative cancer treatments to patients. The company generates revenue through various channels, including partnerships with biotech firms, licensing agreements, and potentially through the sale of its developed drugs.
In summary, Nodus Oncology combines scientific innovation with strategic commercial execution to address critical needs in cancer treatment. The company is well-positioned to make significant contributions to the oncology market through its robust development programs and experienced leadership team.
Keywords: oncology, cancer drugs, biopharmaceutical, R&D, DNA Damage Response, biotech partnerships, licensing, clinical development, innovative treatments, scientific expertise.